VistaGen Therapeutics Inc., a late clinical-stage biopharmaceutical company, has appointed Elissa Cote as Chief Corporate Development Officer. With nearly 30 years of experience in business development and global partnerships, Cote will focus on advancing Vistagen's clinical-stage pipeline, which includes five novel intranasal pherine candidates targeting six prevalent disorders. She will also lead the evaluation of strategic opportunities and cultivate prospective partnerships for the company.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250625610999) on June 25, 2025, and is solely responsible for the information contained therein.